Unknown

Dataset Information

A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer.


ABSTRACT: Breast cancer (BC) is the most commonly diagnosed cancer globally, with high mortality rates. Targeted drug therapies have revolutionized cancer treatment. For example, treatment with human epidermal receptor 2 (HER2) antagonists has markedly improved the prognosis of patients with HER2-positive BC (HER2 + BC). However, HER2+ metastatic BC (MBC) remains prevalent owing to its resistance to conventional anti-HER2 drugs. Therefore, novel agents are needed to overcome the limitations of existing cancer treatments and to enhance the progression-free and overall survival rates. Progress has been made by optimizing the fragment crystallizable (Fc) domain of trastuzumab, an IgG1 monoclonal, chimeric anti-HER2 antibody, to develop margetuximab. The modified Fc domain of margetuximab enhances its b

SUBMITTER: Alasmari MM 

PROVIDER: S-EPMC9817862 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature